Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/16/2024 | $20.00 | Hold → Buy | Needham |
| 11/16/2023 | Hold | Needham | |
| 12/21/2022 | $9.00 | Underweight | Barclays |
| 6/17/2022 | $20.00 | Neutral | JP Morgan |
| 3/18/2022 | Neutral | Guggenheim |
Third Party Net Sales from Continuing Operations of $103.2 millionNet Loss from Continuing Operations of $(3.0) million; Net Loss margin of (3.0%) Adjusted EBITDA[1] from Continuing Operations of $13.1 million; Adjusted EBITDA[1] margin of 12.7%GAAP diluted EPS from Continuing Operations of $(0.11) and adjusted diluted EPS of $0.12 PALM BEACH GARDENS, Fla., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended September 30, 2024. Management will host a corresponding conference call today, October 30, 2024, at 4:30 p.m. Eastern Time. "In the third quarter we saw an improvement
PALM BEACH GARDENS, Fla., Oct. 16, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental market that develops, manu
Third Party Net Sales from Continuing Operations of $116.8 millionNet Loss from Continuing Operations of $(9.6) million; Net Loss margin of (8.2%) Adjusted EBITDA[1] from Continuing Operations of $16.1 million; Adjusted EBITDA[1] margin of 13.8%Reduced debt to $235.1 million, ended quarter with cash balance from Continuing Operations of $78.6 million PALM BEACH GARDENS, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended June 30, 2024. Management will host a corresponding conference call today, August 1, 2024, at 4:30 p.m. Eastern Time. "We continued to execute in the
Needham upgraded ZimVie from Hold to Buy and set a new price target of $20.00
Needham initiated coverage of ZimVie with a rating of Hold
Barclays initiated coverage of ZimVie with a rating of Underweight and set a new price target of $9.00
10-Q - ZimVie Inc. (0001876588) (Filer)
8-K - ZimVie Inc. (0001876588) (Filer)
10-Q - ZimVie Inc. (0001876588) (Filer)
SC 13G/A - ZimVie Inc. (0001876588) (Subject)
SC 13G - ZimVie Inc. (0001876588) (Subject)
SC 13G - ZimVie Inc. (0001876588) (Subject)
4 - ZimVie Inc. (0001876588) (Issuer)
4 - ZimVie Inc. (0001876588) (Issuer)
4 - ZimVie Inc. (0001876588) (Issuer)
Third Party Net Sales from Continuing Operations of $103.2 millionNet Loss from Continuing Operations of $(3.0) million; Net Loss margin of (3.0%) Adjusted EBITDA[1] from Continuing Operations of $13.1 million; Adjusted EBITDA[1] margin of 12.7%GAAP diluted EPS from Continuing Operations of $(0.11) and adjusted diluted EPS of $0.12 PALM BEACH GARDENS, Fla., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended September 30, 2024. Management will host a corresponding conference call today, October 30, 2024, at 4:30 p.m. Eastern Time. "In the third quarter we saw an improvement
PALM BEACH GARDENS, Fla., Oct. 29, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced management will participate in the upcoming UBS Global Healthcare Conference. Management will be presenting on Tuesday, November 12, 2024 at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time. A live webcast of the event, as well as an archived recording will be available on ZimVie's investor website at investor.zimvie.com. About ZimVieZimVie is a global life sciences leader in the dental market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and r
PALM BEACH GARDENS, Fla., Oct. 16, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental market that develops, manu
ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced the U.S. launch of its GenTek® Genuine Restorative Components product portfolio. The launch expands ZimVie's portfolio of end-to-end prosthetic offerings and follows the recent receipt of FDA 510(k) clearance. ZimVie first launched the GenTek portfolio in Europe in 2019 and has seen tremendous success in that market to date.
Shares of Domino’s Pizza, Inc. (NYSE:DPZ) fell sharply during Thursday's session after the company reported mixed quarterly results. The company reported second-quarter FY24 sales growth of 7.1% year-on-year to $1.097 billion, missing the analyst consensus estimate of $1.103 billion. The company is temporarily suspending its guidance metric of 1,100+ global net stores growth until the full effect of DPE's store opens and closures on international net store growth are known. Domino’s Pizza shares dipped 11.2% to $420.36 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Onconetix, Inc. (NASDAQ:ONCO) climbed 97.6% to $0.2944. On July 15, Oncon